Viral Hepatitis

You have full text access to this OnlineOpen article

Retreating chronic hepatitis C with daily interferon alfacon-1/ribavirin after nonresponse to pegylated interferon/ribavirin: DIRECT results†

  1. Bruce R. Bacon1,†,*,
  2. Mitchell L. Shiffman2,
  3. Flavia Mendes3,
  4. Reem Ghalib4,
  5. Tarek Hassanein5,
  6. Giuseppe Morelli6,
  7. Shobha Joshi7,
  8. Kenneth Rothstein8,
  9. Paul Kwo9,
  10. Norman Gitlin10

Article first published online: 2 FEB 2009

DOI: 10.1002/hep.22871

Issue

Hepatology

Hepatology

Volume 49, Issue 6, pages 1838–1846, June 2009

Additional Information

How to Cite

Bacon, B. R., Shiffman, M. L., Mendes, F., Ghalib, R., Hassanein, T., Morelli, G., Joshi, S., Rothstein, K., Kwo, P. and Gitlin, N. (2009), Retreating chronic hepatitis C with daily interferon alfacon-1/ribavirin after nonresponse to pegylated interferon/ribavirin: DIRECT results. Hepatology, 49: 1838–1846. doi: 10.1002/hep.22871

Author Information

  1. 1

    Saint Louis University Liver Center, Saint Louis University School of Medicine, St. Louis, MO

  2. 2

    Hepatology Section, Virginia Commonwealth University Medical Center, Richmond, VA

  3. 3

    Division of Hepatology, University of Miami Miller School of Medicine, Miami, FL

  4. 4

    Liver Institute at Methodist Hospital, Dallas, TX

  5. 5

    Division of Gastroenterology and Hepatology, University of California San Diego, San Diego, CA

  6. 6

    Division of Gastroenterology and Hepatology, University of Florida, Gainesville, FL

  7. 7

    Division of Gastroenterology and Hepatology, Tulane University Hospital and Clinic, New Orleans, LA

  8. 8

    Albert Einstein Center for Liver Disease, Philadelphia, PA

  9. 9

    Division of Gastroenterology and Hepatology, Indiana University School of Medicine, Indianapolis IN

  10. 10

    Division of Gastroenterology and Hepatology, Emory Crawford Long Hospital, Atlanta, GA

  1. †

    Potential conflict of interest: Nothing to report.

*Division of Gastroenterology and Hepatology, Saint Louis University School of Medicine, 3635 Vista Avenue at Grand Boulevard, St. Louis, MO 63110-0250

  1. †

    Potential conflict of interest: Nothing to report.

Publication History

  1. Issue published online: 28 MAY 2009
  2. Article first published online: 2 FEB 2009
  3. Accepted manuscript online: 2 FEB 2009 12:00AM EST
  4. Manuscript Accepted: 24 JAN 2009
  5. Manuscript Received: 21 AUG 2008

Funded by

  • InterMune, Inc.
  • Valeant Pharmaceuticals International
  • Three Rivers Pharmaceuticals

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (244K)

REFERENCES

  • 1
    Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-982.
  • 2
    Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-965.
  • 3
    Fartoux L, Degos F, Trepo C, Goria O, Cales P, Tran A, et al. Effect of prolonged interferon therapy on the outcome of hepatitis C virus-related cirrhosis: a randomized trial. Clin Gastroenterol Hepatol 2007; 5: 502-507.
  • 4
    Helbling B, Jochum W, Stamenic I, Knopfli M, Cerny A, Borovicka J, et al. HCV-related advanced fibrosis/cirrhosis: randomized controlled trial of pegylated interferon alpha-2a and ribavirin. J Viral Hepat 2006; 13: 762-769.
    Direct Link:
  • 5
    Kobayashi S, Takeda T, Enomoto M, Tamori A, Kawada N, Habu D, et al. Development of hepatocellular carcinoma in patients with chronic hepatitis C who had a sustained virological response to interferon therapy: a multicenter, retrospective cohort study of 1124 patients. Liver Int 2007; 27: 186-191.
    Direct Link:
  • 6
    Shiffman ML. Chronic hepatitis C: treatment of pegylated interferon/ribavirin nonresponders. Curr Gastroenterol Rep 2006; 8: 46-52.
  • 7
    Keeffe EB. Future treatment of chronic hepatitis C. Antivir Ther 2007; 12: 1015-1025.
  • 8
    DiBisceglie A., Shiffman ML, Everson GT, Lindsay KL, Everhart JE, Wright EC, et al. Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med 2008; 359: 2429-2441.
  • 9
    Jensen DB, Freilich B, Andreone P, DiBisceglie A, Brandão-Mello CE, Reddy KR, et al. Pegylated interferon alfa-2a (40kD) plus ribavirin (RBV) in prior non-responders to pegylated interferon alfa-2b (12kD)/RBV: final efficacy and safety outcomes of the REPEAT study [abstract LB4]. HEPATOLOGY 2007; 46(Suppl): 291A–292A.
  • 10
    Kaiser S, Hass H, Gregor M. Successful retreatment of peginterferon nonresponder patients with chronic hepatitis C with high dose consensus interferon induction therapy [Abstract 125]. Gastroenterology 2004; 126(Suppl 2): A-668.
  • 11
    Kaiser S, Hass HG, Bissinger L, Gregor M. Comparison of daily consensus interferon versus peginterferon alfa 2a extended therapy of 72 weeks for peginterferon/ribavirin relapse patients with chronic hepatitis C [Abstract S1060]. Gastroenterology 2006; 130(Suppl 2): A-784.
  • 12
    Rustgi VK, Esposito S, Hamzeh FM, Shiffman ML. Peginterferon alfa-2a/ribavirin in hepatitis C virus patients nontolerant or nonresponsive to peginterferon alfa-2b/ribavirin. Aliment Pharmacol Ther 2008; 27: 433-440.
    Direct Link:
  • 13
    Hassanein T, Ghalib R, Zein N, Rothstein KD, Joshi SN, Kwo PY, et al. Analysis of relapse rates in pegylated interferon and ribavirin non-responders treated with daily consensus interferon and ribavirin [Abstract 1319]. HEPATOLOGY 2007; 46: A1319.
  • 14
    Leevy CB. Consensus interferon and ribavirin in patients with chronic hepatitis C who were nonresponders to pegylated interferon alfa-2b and ribavirin. Dig Dis Sci 2008; 53: 1961-1966.
  • 15
    Afdhal NH, Levine R, Brown RJ, Freilich B, O'Brien M, Brass C. Colchicine versus peg-interferon alfa 2b long term therapy: results of the 4 year COPILOT trial [Abstract 3]. J Hepatol 2008; 48(Suppl): S4.
  • 16
    Jensen D, Di Bisceglie A, Gitlin N, Freilich B, Reddy K, Feinman V, et al. Peginterferon alfa-2a (40KD) plus ribavirin (RBV) in pegylated interferon alfa-2b (12KD)/ribavirin non-responders: week 12 efficacy and safety outcomes of the REPEAT study. Gastroenterology 2006; 130; T1800.
  • 17
    Jensen D, Di Bisceglie A, Gitlin N, Freilich B, Reddy K, Feinman V, et al. Type of response to prior pegylated interferon alfa-2b (12kd)/rbv predicts subsequent response to retreatment with peginterferon alfa-2a (40KD)/RBV. Gastroenterology 2008; 134: S1937.
  • 18
    Kaiser S, Boecher W, Lutze B, Sauter B, Bissinger L, Werner C, et al. Treatment of peginterferon/ribavirin nonresponders with daily dosing of consensus interferon and ribavirin: preliminary results of the German Consensus Interferon Multicenter Study [Abstract 1306]. HEPATOLOGY 2007; 46 Suppl:817A.
  • 19
    Ghalib RH, Levine CD, Friedman DA, Rashdan S, Schwartz AG, Weinstein J. Consensus interferon plus ribavirin therapy in patients who are nonresponders or relapsers to prior PEG IFN plus ribavirin. Gastroenterology 2007; 46: M1874.
  • 20
    Harrison SA. Small molecules and novel treatment for chronic hepatitis C virus infection. Am J Gastroenterol 2007; 102: 2332-2338.
    Direct Link:
View Full Article (HTML) Get PDF (244K)